Wontech, Daishin Balance No. 8 SPAC and Merger Submission of Securities Report

14 Apr 2022

Wontech (CEO Jong-won Kim, Jung-hyun Kim), a global healthcare company, which is in charge of the securities company supervised by Daishin Securities, submitted a securities report to the Financial Services Commission on the 1st for a merger and listing with Daishin Balance No. 8 Special Purpose Acquisition Company (SPAC). It was announced that the public offering process had begun in earnest to enter the stock market.
According to the securities report, the merger price of Wontech and Daishin Balance No. 8 SPAC is KRW 2,000, the merger ratio is 1:12.8635762, and the exercise period of appraisal rights is until June 1. The total number of shares issued after the merger is 87,036,952, the date of the merger is June 14, and the expected date of listing of the merged new stocks is June 30.

An official from Wontech said, “We are preparing for the remaining listing schedule and aiming to be listed on the KOSDAQ within the first half of this year. Wontech will focus on developing new and overseas markets to become a global healthcare company."

Since its establishment in 1999, Wontech, a first-generation laser energy medical device company in Korea, has led the market by launching products that reflect customer needs and clinical know-how based on differentiated technology. Since then, the company has been preparing for the post-COVID-19 era, advancing original technology for laser and energy-based medical devices, and equipped with the world's largest product lineup, including surgical laser, aesthetic laser, RF (high frequency) and HIFU (ultrasonic wave). Wontech is increasing its market share in the market and overseas markets.


Wontech succeeded in turning around by recording sales of 51.1 billion won and operating profit of 11 billion won in 2021, and laid the foundation for future leaps forward.


[Wontech "Oligio" model So-yeon Kim]

Copyright (c) 2022 WON TECH Co., Ltd. All Rights Reserved.